To review the normal function of the growth hormone (GH) insulin-like growth factor (IGF) axis, how it is altered in end-stage renal failure, how this may contribute to malnutrition in dialysis patients, and how therapy with recombinant human growth hormone (rHuGH) and recombinant human IGF-I (rHuIGF-1)might be used to treat malnutrition in these patients.
Data Sources
Studies in the literature dealing with the GH-IGF endocrine axis and its role in uremic malnutrition.
Study Selection
Eight studies in which uremic adults were treated with either rHuGH or rHuIGF-I.
Data Extraction
Data were abstracted from all of these studies.
Results
The review shows that there are marked abnormalities of the GH-IGF axis in uremic patients and that these lead to a state of GH resistance, which can be overcome by pharmacological doses of rHuGH. A small number of clinical studies in uremic adults suggests that both rHuGH and rHuIGF-I have dramatic beneficial effects on nutritional status in these patients.
Conclusions
rHuGH and rHuIGF-I have both been shown to have a beneficial effect on nutritional status in shortterm studies on small numbers of patients. Further studies need to be done for longer periods in larger groups of patients. Areas for additional research are suggested.
LowrieE.G., LewN.L.Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.Am J Kidney Dis1990; 15: 458–82.
2.
TeehanB.P., SchleiferC.R., BrownJ.Urea kinetic modeling is an appropriate assessment of adequacy.Semin Dial1992; 55: 189–92.
3.
BlakeP.G., FlowerdewG., BlakeR.M., OreopoulosD.G.Serum albumin in patients on continuous ambulatory peritoneal dialysis -predictors and correlations with outcomes.J Am Soc Nephrol1993; 3: 1501–7.
4.
OwenW.F., LewN.L., LiuY., LowrieE.G., LazarusJ.M.The urea reduction ratio and hemodialysis.N Engl J Med1993; 329: 1001–7.
5.
GotchF., SargentJ.A.A mechanistic analysis of the National Cooperative Dialysis Study (NCDS).Kidney Int1985; 28: 526–34.
6.
BlakeP.G., SombolosK., AbrahamG.Lack of correlation between urea kinetic indices and clinical outcomes in CAPD patients.Kidney Int1991; 39: 700–6.
7.
HartyJ.C., BoultonH., CurwellJThe normalized protein catabolic rate is a flawed marker of nutrition in CAPD patients.Kidney Int1994; 45: 102–9.
8.
MarckmannP.Nutritional status of patients on hemodialysis and peritoneal dialysis.Clin Nephrol1988; 29: 75–8.
9.
FentonS.A., JohnstonN., DelmoreT.Nutritional assessment of continuous ambulatory peritoneal dialysis patients.Trans Am Soc Artif Intern Organs1987; 33: 650–3.
10.
YoungG.A., KoppleJ., LindholmB.Nutritional assessment of CAPD patients: an international study.Am J Kidney Dis1991; 17: 462–71.
11.
FineR.N.Stimulating growth in uremic children.Kidney Int1992; 42: 188–97.
12.
KoppleJ.D.The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure.Miner Electrolyte Metab1992; 18: 269–75.
13.
ZieglerT.R., LazarusJ.M., YoungL.S., HakimR., WilmoreD.W.Effects of recombinanthuman growth hormone in adults receiving maintenance hemodialysis.J Am Soc Nephrol1991; 2: 1130–5.
14.
IkizlerT.A., WingardR.L., BreyerJ.A.Short-term effects of recombinant human growth hormone in CAPD patients.Kidney Int1994; 46: 1178–83.
BaumannG., ShawM.A., AmburnK.Regulation of plasma growth hormone-binding proteins in health and disease.Metabolism1989; 7: 683–9.
22.
SamaanN.A., FreemanR.M.Growth hormone levels in severe renal failure.Metabolism1970; 19: 102–13.
23.
Hea tonA., JohnsonD.G., HaighJ.W., WardM.K., AlbertiKGMM, KerrD.N.S.Twenty-four-hour hormonal and metabolic profiles in uraemic patients before and during treatment with continuous ambulatory peritoneal dialysis.Clin Sci1985; 69: 449–57.
24.
KaganA., ZadikZ., GertlerA., UlmanM., Bar KhayimY.Serum concentrations and peritoneal loss of growth hormone and growth-hormone-binding protein activity in older adults undergoing continuous ambulatory peritoneal dialysis: comparison with haemodialysis patients and normal subjects.Nephrol Dial Transplant1993; 8: 352–6.
25.
ChanW., ValerieK.C., ChanJ.C.M.Expression of insulin-Iike growth factor-l in uremic rats: growth hormone resistance and nutritional intake.Kidney Int1993; 43: 790–5.
26.
TonshoffB., EdenS., WeiserE.Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia.Kidney Int1994; 45: 1085–92.
27.
SchiffrinA., GuidaH., RobitailleP.Increased plasma somatomedin activity in chronic renal failure as determined by acid gel filtration and radioreceptor assay.J Clin Endocrinol Metab1978; 46: 511–14.
28.
PhillipsL.S., KoppleJ.D.Circulating somatomedin activity and sulfate levels in adults with normal and impaired kidney function.Metabolism1981; 30: 1091–5.
29.
PowellD.R., RosenfeldR.G., BakerB.K.Serum somatomedin levels in adults with chronic renal failure.J Clin Endocrinol Metab1986; 63: 1186–92.
30.
LeeP.D.K., HintzR.L., SperryJ.B., BaxterR.C., PowellD.R.I G F binding proteins in growth -retarded children with chronic renal failure.Pediatr Res1989; 26: 308–15.
31.
BlumW.F., RankeM.B., KietzmannK., TonshoffB., MehlsO.Growth hormone resistance and inhibition of somatome din activity by excess of insulin-like growth factor binding protein in uraemia.Pediatr Nephrol1991; 5: 539–44.
32.
FougueD., PengS.C., KoppleJ.D.Impaired metabolic response to recombinant insulin-like growth factor-l in dialysis patients.Kidney Int1995; 47: 876–83.
33.
Postel-VinayM.C., TarA., CrosnierH.Plasma growth hormone-binding activity is low in uraemic children.Pediatr Nephrol1991; 5: 545–7.
34.
JacobV., LeCarpentierJ.E., SalzanoS.IGF-I, a marker of undernutrition in hemodialysis patients.Am J Clin Nutr1990; 52: 39–44.
35.
KochV.H., LippeB.M., NelsonP.A., BoechatM.I., ShermanB.M., FineR.M.Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure.J Pediatr1989; 115: 365–71.
36.
TonshoffB., MehlsO., HeinrichU., BlumW., RankeM.B.Improvement of uremic growth failure by recombinant human growth hormone.Kidney Int1989; 36: S201–4.
37.
Hokken-KoelegaA.C.S., StijnenT., DeMuinck Keizer SchramaSMPFPlacebo-controlled, doubleblind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure.Lancet1991; 338: 585–90.
38.
FineR.N., KohautE.C., BrownD.Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study.J Pediatr1994; 124: 374–82.
39.
SinobeM., SanakaT., HiguchiC., HizukaN., NiheiH., SuginoN.The improvement of catabolic state in hemodialysis patients by recombinant human growth hormone (r-hGH).J Am Soc Nephrol1993; 4: 431.
40.
SchulmannG., WingardR.L., HutchisonR.L., LawrenceP., HakimR.L.The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients.Am J Kidney Dis1993; 21: 527–34.
41.
IkizlerT.A., WingardR.L., FlakollP.J.Effects of recombinant human growth hormone on amino acid profiles in CAPD patients.J Am Soc Nephrol1994; 5: 493.
42.
KangD.H., LeeS.W., KangS.W.Recombinant human growth hormone improved nutritional status of undernourished adult CAPD patients.J Am Soc Nephrol1994; 5: 494.
43.
FineR.N., FineS.E., ShermanB.M.Absorption of recombinant human growth hormone (rHuGH) following intraperitoneal instillation.Perit Dial Int1989; 9: 91–3.
44.
PengS., FouqueD., KoppleJ.D.Insulin-like growth factor I (IGF-I) causes anabolism in malnourished CAPD patients.J Am Soc Nephrol1993; 4: 414.
MillerS.B., MoultonM., O'SheaM., HammermanM.R.Effects of IGF-1 on renal function in end-stage chronic renal failure.Kidney Int1994; 46: 201–7.
47.
KupferS.R., UnderwoodL.E., BaxterR.C., ClemmonsD.R.Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by the use of both agents simultaneously.J Clin Invest1993; 91: 391–6.
48.
HazelS.J., GillespieC.M., MooreR.J.Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination.Kidney Int1994; 46: 58–68.
49.
ChawlaR.K., ParksJ.S., RudmanD.Structural variants of human growth hormone: biochemical, genetic and clinical aspects.Ann Rev Med1983; 34: 529–47.
